Avid Bioservices Inc (CDMO)

[Protector]

corporal, every drug before its first approval never was approaved for anything.

Furthermore I counted on you to remind us about what you just stated:

Most likely to get everyone's mind off of forty cents per share, the failed phase III, and the impending reverse split. But Avid is looking good. Hate to think what would happen if they ever lost their customer.

Good you started with 'Most Likely', that creates room for error :)

That being said, it is best that I write the Bavituximab side effect stuff because it needs accuracy and not just anything (although it may always contain errors, I am human, believe it or not).

With 'just anything' I point at for instance if someone would by error create the impression that Avid had only one big customer who's loss would be a big problem.

If I would write it I would say that Avid once had one big customer but that they reported that this was no longer the case. Furthermore I would emphasise that that one big customer has orders scheduled into 2017 of which that one big customer cannot just back-out without consequences.

Besides the fact that that now, one of the customers, lately shifted more business to Avid it is also using the awarded facilities of Avid, hard to find elsewhere.

Finally I'd say that one does not extend Avid I with Avid II and now with Avid III if dependant on to few customers and without any outlook on new business.

A 56Mil$ backlog, and outlook on 40+Mil$ new orders as reported last Q/CC doesn't sound concerning to me, the more the company has projected number leading to 50-100% increase of turn-over and profits at gross margins around 50% and probably growing with the newer facilities. Add to that 60+Mil$ on the bank and NO CREDITORS and I feel goo.

But then if I wrote all that it wouldn't have a high doom-grade wouldn't it and hence would be less colourful for this board to read :)